Author (year) | Country | Age* | Sample size | Dosage | Follow-up period (weeks) | Â | ||
---|---|---|---|---|---|---|---|---|
 |  |  | Glimepiride | Metformin | Glimepiride | Metformin | Ref | |
Ling (2003) | China | Female 54 (8.3) | 50 | 44 | 1-6Â mg/day | 750-1750Â mg/day | 12 | [33] |
 |  | Male 53 (9.2) |  |  |  |  |  |  |
Ramachandran (2004) | India | 30-60 | 18 | 21 | 1-2Â mg/day | 250-850Â mg/day | 14 | [34] |
Derosa (2004) | Italian | 46-67 | 81 | 83 | 2-4Â mg/day | 2000-3000Â mg/day | 52 | [35] |
Gonzolez (2004) | Mexico | 40-65 | 37 | 33 | 2Â mg/day | 2000Â mg/day | 12 | [36] |
Rong (2004) | China | 42 (11) | 98 | 100 | 4Â mg/day | 1500Â mg/day | 12 | [22] |
Tang (2004) | China | 35-70 | 33 | 29 | 1-2Â mg/day | 750-1500Â mg/day | 26 | [37] |
Yamanouchi (2005) | Japan | Metformin 54.7 (9.8) | 37 | 39 | 1-2Â mg/day | 750Â mg/day | 52 | [20] |
 |  | Glimepiride 53 (9.2) |  |  |  |  |  |  |
Ning (2006) | China | 35-70 | 51 | 50 | 1-6Â mg/day | 250Â mg bid-750Â mg tid | 52 | [38] |
Wu (2007) | China | 30-70 | 40 | 30 | 1-6Â mg/day | 250-2000Â mg tid | 12 | [39] |
Xu (2007) | China | 35-70 | 34 | 34 | 1-6Â mg/day | 250Â mg to maximum bid | - | [40] |
Li (2007) | China | 32-70 | 35 | 33 | 2-6Â mg/day | 250-1500Â mg bid | 65 | [41] |
Wang (2009) | China | 45 (7) | 49 | 50 | 4-6Â mg/day | 1500Â mg/day | 12 | [23] |
Rahman (2011) | Pakistan | Metformin 51.9 (14.1) | 102 | 102 | 2-8Â mg/day | 500-2000Â mg/day | 52 | [42] |
 |  | Glimepiride 52 (15.4) |  |  |  |  |  |  |
Yoon (2011) | Korea | 30-65 | 118 | 114 | 2Â mg/day | 500Â mg/day | 48 | [21] |
Wang (2011) | China | 33-70 | 68 | 68 | 2Â mg/day | 500Â mg bid | 12 | [43] |